The Global Biosimulation Market was valued at around US$ 2.6 billion in 2021, with a projected CAGR of 21.5% for the next ten years the market is likely to reach a valuation of US$ 20.9 Billion by the end of 2032. The need for developing new drugs to compact the developing diseases will drive the demand for biosimulation.
| Report Attributes | Details |
|---|---|
| Estimated Market Value (2022E) | US$ 3.1 Billion |
| Forecasted Market Value (2032F) | US$ 20.9 Billion |
| Global Market Growth Rate (2022 to 2032) | 21.5% CAGR |
| United States Growth Rate (2022 to 2032) | ~21.6% CAGR |
| Key Companies Covered |
|
Future Market Insight’s analysis reveals that most of the revenue is generated from biosimulation software. On the other hand, drug development in deployment mode will be the most lucrative with a CAGR of 22.8% during the forecast period.
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
The global market for Biosimulation registered a CAGR of 15.8% from 2015 to 2021. The market growth is projected to surge due to technological advancement in software for biosimulation. In 2021, the global market size of biosimulation was valued at US$ 2.6 Billion and is estimated to increase to a valuation of US$ 3.1 Billion in 2022.
Biosimulation is the use of computer-aided mathematical models to simulate biological processes. Biosimulation has various applications like developing new drugs and discovering new drugs. The drug discovery and development process is expensive, and the failure of a therapeutic molecule in the late stages of drug development results in a massive waste of time, money, and other resources. As a result, a predictive tool is required to aid in predicting the future results of drug development through simulation of the biological processes involved.
Biosimulation helps to simulate the effect of drugs on the body with the help of simulation. Pharmaceutical manufacturers are using biosimulation throughout the drug development process to identify the positive and negative effects of their drug can have on the people if the drug is used.
The global biosimulation market has predicted to surge ahead at a CAGR of 21.5% and record sales worth US$ 20.9 Billion by the end of 2032. US will continue to be the largest procurer of biosimulation throughout the analysis period accounting for over US$ 7.5 Billion absolute dollar opportunity in the coming 10-year epoch.
Rising global healthcare spending will increase spending on developing drugs, which will drive revenue for biosimulation. Many drugs for mimic diseases are developed using biosimulation. Computers operating sickness simulations with the aid of biosimulation software can be used to conduct virtual clinical trials for new pharmaceutical treatments. Developing a new drug requires significant research and studies. Every stage of drug development from clinical trials to the approval of the drug has a serious chance of failure. Biosimulation lowers these odds by predicting these failures in the development process. Also, it lowers the cost of pharmaceutical companies by lowering the number of clinical trials.
Principal Consultant
Biosimulation uses mathematical equations to depict a real-life process that occurs within the human body. Researchers may simulate a wide range of scenarios and examine the behavior of a human system in diverse settings since it can duplicate human biological elements and their interactions with medications when they are put into the system.
In order to obtain a better result, skilled expertise is required to perform the biosimulation software. The demand for skilled expertise is high in research laboratories and companies. In addition, this process is very complex and highly technical as they involve various laboratory documentation systems. In order to overcome this issue, researchers must receive proper training and assistance. These factors make biosimulation development time-consuming, thus limiting its adoption among researchers.
North America holds the largest market for biosimulation. The rising chronic disease among the population in the region and regulations implemented by the governments for patient safety and treatment standards is driving the demand for biosimulation in the region. In silico modeling is being used to boost the standard of patient care and safety. This is particularly true for the implementation of regulatory laws that have high standards for the safety and care of patients.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
The encouraging government policies in the USA and the rising healthcare expenditure due to the dominance of chronic diseases are key factors that are rising drug development and discovery in the USA. The market for biosimulation in the USA has projected to reach a valuation of US$ 8.7 Billion in 2032.
The government policies for developing quality pharmaceutical drugs and the Chinese government‘s commitment to develop and increase innovation in its healthcare system are driving the market for biosimulation in China. Chinese government’s plan to be a global leader in drug development is attracting drug development and pharmaceutical companies to China for the development of new drugs, which will further increase the demand for the biosimulation market over the years. The market for biosimulation in China is forecasted to reach a valuation of US$ 1.7 Billion by 2032.
The market in the United Kingdom is projected to reach a valuation of US$ 880 million by 2032. The market is expected to grow at a CAGR of 20.6% from 2022 to 2032 to gross an absolute dollar opportunity of US$ 336 million.
The market for biosimulation in Japan is expected to reach US$ 1.2 Billion by 2032. Growing at a CAGR of 25.1% during the forecast period, the market is likely to garner an absolute dollar opportunity of US$ 1.1 Billion.
The market through the CROs segment is anticipated to grow at the fastest rate during the forecast period. The growing tendency of firms to cut total spending is expected to drive segment growth. Other factors like increased efficiency and the ability to focus on core areas for company development will also drive the use of biosimulation in CROs.
The key companies operating in the biosimulation market include Certara, Dassault Systemes, Advanced Chemistry Development, Simulation Plus Inc., Schrodinger, Inc., Chemical Computing Group, Physiomics Plc, Rosa & Co. LLC, BioSimulation Consulting Inc., Genedata AG, Instem Group of Companies, PPD, Inc., Insilico Biotechnology AG, Rhenovia Pharma, LeadInvent Technologies, Nuventra Pharma, and In Silico Biosciences.
Some of the recent developments by key providers of biosimulation are as follows:
Similarly, the team at Future Market Insights has tracked recent developments related to companies offering Biosimulation, which is available in the full report.
The global biosimulation market was valued at US$ 2.6 billion in 2021.
The biosimulation industry is set to witness a high growth rate of 21.5% over the forecasted period and be valued at US$ 20.9 billion by 2032.
The Biosimulation Market expanded at a CAGR of 15.8% from 2015 through 2021.
Certara, Dassault Systemes, Advanced Chemistry Development, Simulation Plus Inc, and Schrodinger, Inc. are the key providers of biosimulation.
The USA, United Kingdom, China Japan, and South Korea are expected to drive the most sales growth of Biosimulation.
The market in the USA has forecasted to account for over 40% of the global market share in 2032.
1. Executive Summary | Biosimulation Market 1.1. Global Market Outlook 1.2. Demand-side Trends 1.3. Supply-side Trends 1.4. Technology Roadmap Analysis 1.5. Analysis and Recommendations 2. Market Overview 2.1. Market Coverage / Taxonomy 2.2. Market Definition / Scope / Limitations 3. Market Background 3.1. Market Dynamics 3.1.1. Drivers 3.1.2. Restraints 3.1.3. Opportunity 3.1.4. Trends 3.2. Scenario Forecast 3.2.1. Demand in Optimistic Scenario 3.2.2. Demand in Likely Scenario 3.2.3. Demand in Conservative Scenario 3.3. Investment Feasibility Matrix 3.4. Regulatory Landscape 3.4.1. By Key Regions 3.4.2. By Key Countries 4. Global Market Analysis 2015 to 2021 and Forecast, 2022 to 2032 4.1. Historical Market Size Value (US$ million) Analysis, 2015 to 2021 4.2. Current and Future Market Size Value (US$ million) Projections, 2022 to 2032 4.2.1. Y-o-Y Growth Trend Analysis 4.2.2. Absolute $ Opportunity Analysis 5. Global Market Analysis 2015 to 2021 and Forecast 2022 to 2032, By Product Type 5.1. Introduction / Key Findings 5.2. Historical Market Size Value (US$ million) Analysis By Product Type, 2015 to 2021 5.3. Current and Future Market Size Value (US$ million) Analysis and Forecast By Product Type, 2022 to 2032 5.3.1. Software 5.3.2. Services 5.3.2.1. In-house Services 5.3.2.2. Contract Services 5.4. Y-o-Y Growth Trend Analysis By Product Type, 2015 to 2021 5.5. Absolute $ Opportunity Analysis By Product Type, 2022 to 2032 6. Global Market Analysis 2015 to 2021 and Forecast 2022 to 2032, By Deployment Mode 6.1. Introduction / Key Findings 6.2. Historical Market Size Value (US$ million) Analysis By Deployment Mode, 2015 to 2021 6.3. Current and Future Market Size Value (US$ million) Analysis and Forecast By Deployment Mode, 2022 to 2032 6.3.1. Drug Development 6.3.2. Drug Discovery 6.3.3. Other Applications 6.4. Y-o-Y Growth Trend Analysis By Deployment Mode, 2015 to 2021 6.5. Absolute $ Opportunity Analysis By Deployment Mode, 2022 to 2032 7. Global Market Analysis 2015 to 2021 and Forecast 2022 to 2032, By End Use 7.1. Introduction / Key Findings 7.2. Historical Market Size Value (US$ million) Analysis By End Use, 2015 to 2021 7.3. Current and Future Market Size Value (US$ million) Analysis and Forecast By End Use, 2022 to 2032 7.3.1. Pharmaceutical & Biotechnology Companies 7.3.2. CROs 7.3.3. Regulatory Authorities 7.3.4. Academic Research Institutions 7.4. Y-o-Y Growth Trend Analysis By End Use, 2015 to 2021 7.5. Absolute $ Opportunity Analysis By End Use, 2022 to 2032 8. Global Market Analysis 2015 to 2021 and Forecast 2022 to 2032, By Region 8.1. Introduction 8.2. Historical Market Size Value (US$ million) Analysis By Region, 2015 to 2021 8.3. Current Market Size Value (US$ million) Analysis and Forecast By Region, 2022 to 2032 8.3.1. North America 8.3.2. Latin America 8.3.3. Europe 8.3.4. East Asia 8.3.5. South Asia 8.3.6. Oceania 8.3.7. Middle East and Africa (MEA) 8.4. Market Attractiveness Analysis By Region 9. North America Market Analysis 2015 to 2021 and Forecast 2022 to 2032, By Country 9.1. Historical Market Size Value (US$ million) Trend Analysis By Market Taxonomy, 2015 to 2021 9.2. Market Size Value (US$ million) Forecast By Market Taxonomy, 2022 to 2032 9.2.1. By Country 9.2.1.1. The USA 9.2.1.2. Canada 9.2.2. By Product Type 9.2.3. By Deployment Mode 9.2.4. By End Use 9.3. Market Attractiveness Analysis 9.3.1. By Country 9.3.2. By Product Type 9.3.3. By Deployment Mode 9.3.4. By End Use 9.4. Key Takeaways 10. Latin America Market Analysis 2015 to 2021 and Forecast 2022 to 2032, By Country 10.1. Historical Market Size Value (US$ million) Trend Analysis By Market Taxonomy, 2015 to 2021 10.2. Market Size Value (US$ million) Forecast By Market Taxonomy, 2022 to 2032 10.2.1. By Country 10.2.1.1. Brazil 10.2.1.2. Mexico 10.2.1.3. Argentina 10.2.1.4. Rest of Latin America 10.2.2. By Product Type 10.2.3. By Deployment Mode 10.2.4. By End Use 10.3. Market Attractiveness Analysis 10.3.1. By Country 10.3.2. By Product Type 10.3.3. By Deployment Mode 10.3.4. By End Use 10.4. Key Takeaways 11. Europe Market Analysis 2015 to 2021 and Forecast 2022 to 2032, By Country 11.1. Historical Market Size Value (US$ million) Trend Analysis By Market Taxonomy, 2015 to 2021 11.2. Market Size Value (US$ million) Forecast By Market Taxonomy, 2022 to 2032 11.2.1. By Country 11.2.1.1. Germany 11.2.1.2. Italy 11.2.1.3. France 11.2.1.4. The United Kingdom 11.2.1.5. Spain 11.2.1.6. Russia 11.2.1.7. BENELUX 11.2.1.8. Rest of Europe 11.2.2. By Product Type 11.2.3. By Deployment Mode 11.2.4. By End Use 11.3. Market Attractiveness Analysis 11.3.1. By Country 11.3.2. By Product Type 11.3.3. By Deployment Mode 11.3.4. By End Use 11.4. Key Takeaways 12. East Asia Market Analysis 2015 to 2021 and Forecast 2022 to 2032, By Country 12.1. Historical Market Size Value (US$ million) Trend Analysis By Market Taxonomy, 2015 to 2021 12.2. Market Size Value (US$ million) Forecast By Market Taxonomy, 2022 to 2032 12.2.1. By Country 12.2.1.1. China 12.2.1.2. Japan 12.2.1.3. South Korea 12.2.2. By Product Type 12.2.3. By Deployment Mode 12.2.4. By End Use 12.3. Market Attractiveness Analysis 12.3.1. By Country 12.3.2. By Product Type 12.3.3. By Deployment Mode 12.3.4. By End Use 12.4. Key Takeaways 13. South Asia Market Analysis 2015 to 2021 and Forecast 2022 to 2032, By Country 13.1. Historical Market Size Value (US$ million) Trend Analysis By Market Taxonomy, 2015 to 2021 13.2. Market Size Value (US$ million) Forecast By Market Taxonomy, 2022 to 2032 13.2.1. By Country 13.2.1.1. India 13.2.1.2. Thailand 13.2.1.3. Malaysia 13.2.1.4. Indonesia 13.2.1.5. Rest of South Asia 13.2.2. By Product Type 13.2.3. By Deployment Mode 13.2.4. By End Use 13.3. Market Attractiveness Analysis 13.3.1. By Country 13.3.2. By Product Type 13.3.3. By Deployment Mode 13.3.4. By End Use 13.4. Key Takeaways 14. Oceania Market Analysis 2015 to 2021 and Forecast 2022 to 2032, By Country 14.1. Historical Market Size Value (US$ million) Trend Analysis By Market Taxonomy, 2015 to 2021 14.2. Market Size Value (US$ million) Forecast By Market Taxonomy, 2022 to 2032 14.2.1. By Country 14.2.1.1. Australia 14.2.1.2. New Zealand 14.2.2. By Product Type 14.2.3. By Deployment Mode 14.2.4. By End Use 14.3. Market Attractiveness Analysis 14.3.1. By Country 14.3.2. By Product Type 14.3.3. By Deployment Mode 14.3.4. By End Use 14.4. Key Takeaways 15. MEA Market Analysis 2015 to 2021 and Forecast 2022 to 2032, By Country 15.1. Historical Market Size Value (US$ million) Trend Analysis By Market Taxonomy, 2015 to 2021 15.2. Market Size Value (US$ million) Forecast By Market Taxonomy, 2022 to 2032 15.2.1. By Country 15.2.1.1. GCC 15.2.1.2. Rest of MEA 15.2.2. By Product Type 15.2.3. By Deployment Mode 15.2.4. By End Use 15.3. Market Attractiveness Analysis 15.3.1. By Country 15.3.2. By Product Type 15.3.3. By Deployment Mode 15.3.4. By End Use 15.4. Key Takeaways 16. Key Countries Market Analysis 16.1. The USA 16.1.1. Pricing Analysis 16.1.2. Market Share Analysis, 2021 16.1.2.1. By Product Type 16.1.2.2. By Deployment Mode 16.1.2.3. By End Use 16.2. Canada 16.2.1. Pricing Analysis 16.2.2. Market Share Analysis, 2021 16.2.2.1. By Product Type 16.2.2.2. By Deployment Mode 16.2.2.3. By End Use 16.3. Brazil 16.3.1. Pricing Analysis 16.3.2. Market Share Analysis, 2021 16.3.2.1. By Product Type 16.3.2.2. By Deployment Mode 16.3.2.3. By End Use 16.4. Mexico 16.4.1. Pricing Analysis 16.4.2. Market Share Analysis, 2021 16.4.2.1. By Product Type 16.4.2.2. By Deployment Mode 16.4.2.3. By End Use 16.5. Argentina 16.5.1. Pricing Analysis 16.5.2. Market Share Analysis, 2021 16.5.2.1. By Product Type 16.5.2.2. By Deployment Mode 16.5.2.3. By End Use 16.6. Germany 16.6.1. Pricing Analysis 16.6.2. Market Share Analysis, 2021 16.6.2.1. By Product Type 16.6.2.2. By Deployment Mode 16.6.2.3. By End Use 16.7. Italy 16.7.1. Pricing Analysis 16.7.2. Market Share Analysis, 2021 16.7.2.1. By Product Type 16.7.2.2. By Deployment Mode 16.7.2.3. By End Use 16.8. France 16.8.1. Pricing Analysis 16.8.2. Market Share Analysis, 2021 16.8.2.1. By Product Type 16.8.2.2. By Deployment Mode 16.8.2.3. By End Use 16.9. The United Kingdom 16.9.1. Pricing Analysis 16.9.2. Market Share Analysis, 2021 16.9.2.1. By Product Type 16.9.2.2. By Deployment Mode 16.9.2.3. By End Use 16.10. Spain 16.10.1. Pricing Analysis 16.10.2. Market Share Analysis, 2021 16.10.2.1. By Product Type 16.10.2.2. By Deployment Mode 16.10.2.3. By End Use 16.11. Russia 16.11.1. Pricing Analysis 16.11.2. Market Share Analysis, 2021 16.11.2.1. By Product Type 16.11.2.2. By Deployment Mode 16.11.2.3. By End Use 16.12. BENELUX 16.12.1. Pricing Analysis 16.12.2. Market Share Analysis, 2021 16.12.2.1. By Product Type 16.12.2.2. By Deployment Mode 16.12.2.3. By End Use 16.13. China 16.13.1. Pricing Analysis 16.13.2. Market Share Analysis, 2021 16.13.2.1. By Product Type 16.13.2.2. By Deployment Mode 16.13.2.3. By End Use 16.14. Japan 16.14.1. Pricing Analysis 16.14.2. Market Share Analysis, 2021 16.14.2.1. By Product Type 16.14.2.2. By Deployment Mode 16.14.2.3. By End Use 16.15. South Korea 16.15.1. Pricing Analysis 16.15.2. Market Share Analysis, 2021 16.15.2.1. By Product Type 16.15.2.2. By Deployment Mode 16.15.2.3. By End Use 16.16. India 16.16.1. Pricing Analysis 16.16.2. Market Share Analysis, 2021 16.16.2.1. By Product Type 16.16.2.2. By Deployment Mode 16.16.2.3. By End Use 16.17. Thailand 16.17.1. Pricing Analysis 16.17.2. Market Share Analysis, 2021 16.17.2.1. By Product Type 16.17.2.2. By Deployment Mode 16.17.2.3. By End Use 16.18. Malaysia 16.18.1. Pricing Analysis 16.18.2. Market Share Analysis, 2021 16.18.2.1. By Product Type 16.18.2.2. By Deployment Mode 16.18.2.3. By End Use 16.19. Indonesia 16.19.1. Pricing Analysis 16.19.2. Market Share Analysis, 2021 16.19.2.1. By Product Type 16.19.2.2. By Deployment Mode 16.19.2.3. By End Use 16.20. Australia 16.20.1. Pricing Analysis 16.20.2. Market Share Analysis, 2021 16.20.2.1. By Product Type 16.20.2.2. By Deployment Mode 16.20.2.3. By End Use 16.21. New Zealand 16.21.1. Pricing Analysis 16.21.2. Market Share Analysis, 2021 16.21.2.1. By Product Type 16.21.2.2. By Deployment Mode 16.21.2.3. By End Use 16.22. GCC Countries 16.22.1. Pricing Analysis 16.22.2. Market Share Analysis, 2021 16.22.2.1. By Product Type 16.22.2.2. By Deployment Mode 16.22.2.3. By End Use 17. Market Structure Analysis 17.1. Competition Dashboard 17.2. Competition Benchmarking 17.3. Market Share Analysis of Top Players 17.3.1. By Regional 17.3.2. By Product Type 17.3.3. By Deployment Mode 17.3.4. By End Use 18. Competition Analysis 18.1. Competition Deep Dive 18.1.1. Certara 18.1.1.1. Overview 18.1.1.2. Product Portfolio 18.1.1.3. Profitability by Market Segments 18.1.1.4. Sales Footprint 18.1.1.5. Strategy Overview 18.1.1.5.1. Marketing Strategy 18.1.1.5.2. Product Strategy 18.1.1.5.3. Channel Strategy 18.1.2. Dassault Systemes 18.1.2.1. Overview 18.1.2.2. Product Portfolio 18.1.2.3. Profitability by Market Segments 18.1.2.4. Sales Footprint 18.1.2.5. Strategy Overview 18.1.2.5.1. Marketing Strategy 18.1.2.5.2. Product Strategy 18.1.2.5.3. Channel Strategy 18.1.3. Advanced Chemistry Development 18.1.3.1. Overview 18.1.3.2. Product Portfolio 18.1.3.3. Profitability by Market Segments 18.1.3.4. Sales Footprint 18.1.3.5. Strategy Overview 18.1.3.5.1. Marketing Strategy 18.1.3.5.2. Product Strategy 18.1.3.5.3. Channel Strategy 18.1.4. Simulation Plus Inc 18.1.4.1. Overview 18.1.4.2. Product Portfolio 18.1.4.3. Profitability by Market Segments 18.1.4.4. Sales Footprint 18.1.4.5. Strategy Overview 18.1.4.5.1. Marketing Strategy 18.1.4.5.2. Product Strategy 18.1.4.5.3. Channel Strategy 18.1.5. Schrodinger, Inc. 18.1.5.1. Overview 18.1.5.2. Product Portfolio 18.1.5.3. Profitability by Market Segments 18.1.5.4. Sales Footprint 18.1.5.5. Strategy Overview 18.1.5.5.1. Marketing Strategy 18.1.5.5.2. Product Strategy 18.1.5.5.3. Channel Strategy 18.1.6. Chemical Computing Group 18.1.6.1. Overview 18.1.6.2. Product Portfolio 18.1.6.3. Profitability by Market Segments 18.1.6.4. Sales Footprint 18.1.6.5. Strategy Overview 18.1.6.5.1. Marketing Strategy 18.1.6.5.2. Product Strategy 18.1.6.5.3. Channel Strategy 18.1.7. Physiomics Plc 18.1.7.1. Overview 18.1.7.2. Product Portfolio 18.1.7.3. Profitability by Market Segments 18.1.7.4. Sales Footprint 18.1.7.5. Strategy Overview 18.1.7.5.1. Marketing Strategy 18.1.7.5.2. Product Strategy 18.1.7.5.3. Channel Strategy 18.1.8. Rosa & Co. LLC 18.1.8.1. Overview 18.1.8.2. Product Portfolio 18.1.8.3. Profitability by Market Segments 18.1.8.4. Sales Footprint 18.1.8.5. Strategy Overview 18.1.8.5.1. Marketing Strategy 18.1.8.5.2. Product Strategy 18.1.8.5.3. Channel Strategy 18.1.9. Consulting Inc. 18.1.9.1. Overview 18.1.9.2. Product Portfolio 18.1.9.3. Profitability by Market Segments 18.1.9.4. Sales Footprint 18.1.9.5. Strategy Overview 18.1.9.5.1. Marketing Strategy 18.1.9.5.2. Product Strategy 18.1.9.5.3. Channel Strategy 18.1.10. Genedata AG 18.1.10.1. Overview 18.1.10.2. Product Portfolio 18.1.10.3. Profitability by Market Segments 18.1.10.4. Sales Footprint 18.1.10.5. Strategy Overview 18.1.10.5.1. Marketing Strategy 18.1.10.5.2. Product Strategy 18.1.10.5.3. Channel Strategy 18.1.11. Instem Group of Companies 18.1.11.1. Overview 18.1.11.2. Product Portfolio 18.1.11.3. Profitability by Market Segments 18.1.11.4. Sales Footprint 18.1.11.5. Strategy Overview 18.1.11.5.1. Marketing Strategy 18.1.11.5.2. Product Strategy 18.1.11.5.3. Channel Strategy 18.1.12. PPD, Inc. 18.1.12.1. Overview 18.1.12.2. Product Portfolio 18.1.12.3. Profitability by Market Segments 18.1.12.4. Sales Footprint 18.1.12.5. Strategy Overview 18.1.12.5.1. Marketing Strategy 18.1.12.5.2. Product Strategy 18.1.12.5.3. Channel Strategy 18.1.13. Insilico Biotechnology AG 18.1.13.1. Overview 18.1.13.2. Product Portfolio 18.1.13.3. Profitability by Market Segments 18.1.13.4. Sales Footprint 18.1.13.5. Strategy Overview 18.1.13.5.1. Marketing Strategy 18.1.13.5.2. Product Strategy 18.1.13.5.3. Channel Strategy 18.1.14. Rhenovia Pharma 18.1.14.1. Overview 18.1.14.2. Product Portfolio 18.1.14.3. Profitability by Market Segments 18.1.14.4. Sales Footprint 18.1.14.5. Strategy Overview 18.1.14.5.1. Marketing Strategy 18.1.14.5.2. Product Strategy 18.1.14.5.3. Channel Strategy 18.1.15. LeadInvent Technologies 18.1.15.1. Overview 18.1.15.2. Product Portfolio 18.1.15.3. Profitability by Market Segments 18.1.15.4. Sales Footprint 18.1.15.5. Strategy Overview 18.1.15.5.1. Marketing Strategy 18.1.15.5.2. Product Strategy 18.1.15.5.3. Channel Strategy 18.1.16. Nuventra Pharma 18.1.16.1. Overview 18.1.16.2. Product Portfolio 18.1.16.3. Profitability by Market Segments 18.1.16.4. Sales Footprint 18.1.16.5. Strategy Overview 18.1.16.5.1. Marketing Strategy 18.1.16.5.2. Product Strategy 18.1.16.5.3. Channel Strategy 18.1.17. In Silico Biosciences 18.1.17.1. Overview 18.1.17.2. Product Portfolio 18.1.17.3. Profitability by Market Segments 18.1.17.4. Sales Footprint 18.1.17.5. Strategy Overview 18.1.17.5.1. Marketing Strategy 18.1.17.5.2. Product Strategy 18.1.17.5.3. Channel Strategy 19. Assumptions & Acronyms Used 20. Research Methodology
Chemicals & Materials
December 2014
REP-GB--89
October 2023
90 pages
Explore Healthcare Insights
View Reports
Biosimulation Market
